Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elbl

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Vnitrni Lekarstvi|June 8, 2006
[Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy]L Elbl, I Vásová, M Navrátil, et al.
Neoplasma|April 1, 2006
Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphomaL Elbl, I Vasova, I Tomaskova, et al.
Vnitrni Lekarstvi|September 1, 1994
[Difficulties in the therapy of primary amyloidosis]Z Adam, L Elbl, J Vorlícek, et al.
Vnitrni Lekarstvi|January 12, 2005
[Involvement of the cardiac muscle in anemia]L Elbl, M Penka, V Chaloupka, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 19, 2001
The C766T low-density lipoprotein receptor related protein polymorphism and coronary artery disease, plasma lipoproteins, and longevity in the Czech populationP Benes, J Muzík, J Benedík, et al.
Vnitrni Lekarstvi|August 1, 1994
[Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)]Z Adam, L Elbl, J Vorlícek, et al.
Journal of Chemotherapy (Florence, Italy)|June 2, 2006
Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimensL Elbl, I Vasova, Z Kral, et al.
Acta Medica Austriaca|January 1, 1994
Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD)Z Adam, L Elbl, J Vorlicek, et al.
Vnitrni Lekarstvi|January 11, 2005
[Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas]L Elbl, V Chaloupka, I Vásová, et al.
Molecular Genetics and Metabolism|March 18, 2000
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasiansP Benes, J Muzík, J Benedík, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Vnitrni Lekarstvi|June 8, 2006
[Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy]L Elbl, I Vásová, M Navrátil, et al.
Neoplasma|April 1, 2006
Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphomaL Elbl, I Vasova, I Tomaskova, et al.
Vnitrni Lekarstvi|September 1, 1994
[Difficulties in the therapy of primary amyloidosis]Z Adam, L Elbl, J Vorlícek, et al.
Vnitrni Lekarstvi|January 12, 2005
[Involvement of the cardiac muscle in anemia]L Elbl, M Penka, V Chaloupka, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 19, 2001
The C766T low-density lipoprotein receptor related protein polymorphism and coronary artery disease, plasma lipoproteins, and longevity in the Czech populationP Benes, J Muzík, J Benedík, et al.
Vnitrni Lekarstvi|August 1, 1994
[Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)]Z Adam, L Elbl, J Vorlícek, et al.
Journal of Chemotherapy (Florence, Italy)|June 2, 2006
Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimensL Elbl, I Vasova, Z Kral, et al.
Acta Medica Austriaca|January 1, 1994
Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD)Z Adam, L Elbl, J Vorlicek, et al.
Vnitrni Lekarstvi|January 11, 2005
[Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas]L Elbl, V Chaloupka, I Vásová, et al.
Molecular Genetics and Metabolism|March 18, 2000
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasiansP Benes, J Muzík, J Benedík, et al.
Pageof 4